Evidence map›Paper›PMID 26819251›Full record

ReviewJournal of the American Heart Association2016

Overcoming Challenges With Statin Therapy.

J David Spence, George K Dresser

Abstract readCase ReportsReview
In one paragraph

Review in Journal of the American Heart Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. A comprehensive review and meta-analysis of risk factors for statin-induced myopathy.European journal of clinical pharmacology · 2018 · on this map
    Pooled it
  2. Cardiometabolic Consequences of Targeted Anticancer Therapies.Journal of cardiovascular pharmacology · 2022
    Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Atherosclerosis and Coenzyme QInternational journal of molecular sciences · 2019
    Review
  9. Article
  10. Review
  11. Article
  12. Controlling resistant hypertension.Stroke and vascular neurology · 2018
    Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

J David SpenceStroke Prevention & Atherosclerosis Research Centre, Robarts Research Institute, Western University, London, Ontario, Canada (D.S.) Division of Clinical Pharmacology, Department of Medicine, Western University, London, Ontario, Canada (D.S., G.K.D.).
George K DresserDivision of Clinical Pharmacology, Department of Medicine, Western University, London, Ontario, Canada (D.S., G.K.D.).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Insulin ResistanceBiomarkersCardiovascular DiseasesDiabetes MellitusDrug InteractionsDrug SubstitutionDyslipidemiasHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLipidsMaleMedication AdherenceMiddle AgedMuscular DiseasesPharmacogeneticsPractice Patterns, Physicians'BiomarkersHydroxymethylglutaryl-CoA Reductase InhibitorsLipidsadverse effectsmitochondrial functionPersistencestatinsubiquinone

Identifiers

PMID26819251
PMCPMC4859367

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.